Ulk inhibitors and methods of use thereof
Patent Information
- Application Number
- IL330983
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-06
- Filing Date
- 2025-01-31
- Publication Date
- 2026-08-01
AI Technical Summary
Current autophagy inhibitors, such as chloroquine and hydroxychloroquine, have multiple mechanisms of action and induce retinopathies, necessitating the development of more targeted agents that selectively block autophagy without toxicities, particularly for treating mutant Ras cancers which are highly proliferative and dependent on basal levels of autophagy for survival.
Development of compounds that inhibit ULK kinase activity, including ULK1 and ULK2, represented by Formulas (I) and (II), which are used in pharmaceutical compositions to treat cancers by blocking autophagy and potentially combining with RTK/RAS/MAPK pathway inhibitors, chemotherapeutic agents, and other targeted therapeutics.
The ULK kinase inhibitors effectively block autophagy in tumor cells and host tissues, synergizing with existing therapies to inhibit tumor growth and enhance treatment efficacy in mutant Ras cancers.